@entity700 have recently increased in incidence, and thus it has become important to establish clinical management of these @entity1 . It is also important to evaluate whether these @entity5 are different from preclinical or overt @entity699 in their steroidogenesis. In this study, we therefore examined steroidogenesis of hormonally inactive @entity700 via short-term culture of @entity5 specimens, in addition to an immunohistochemical study of steroidogenic enzymes. Five @entity1 (two @entity1 and three @entity1 ) diagnosed with @entity1636 without any clinical signs of adrenocortical hormonal excess except for @entity101 and disturbed @entity413 tolerance, were recruited for this study. Hormonal findings, including circadian rhythms for @entity701 and ACTH secretion, the response of ACTH to @entity6192 infusion and results of @entity619 suppression test were all within normal limits in these @entity1 . Immunoreactivity for all steroidogenic enzymes involved in @entity701 production was detected in @entity5 cells in all cases examined. Results of in vitro steroidogenesis analysis using short-term culture revealed that levels of @entity701 secretion varied among the cases. There were no differences in the immunolocalization of steroidogenic enzymes and/or the levels of @entity701 secretion between these hormonally inactive @entity5 and preclinical and/or overt @entity699 . @entity2494 -sulfotransferase ( @entity2494 -ST) immunoreactivity in nonneoplastic regions was suppressed in one case in which the @entity5 secreted @entity701 similar to preclinical and/or overt @entity699 . These results demonstrate that the levels of in vitro @entity134 production and/or the immunolocalization of steroidogenic enzymes in hormonally inactive @entity16663 vary markedly and are not overtly different from those of preclinical and/or overt @entity699 .

Analysis of XXXX secretion in hormonally inactive @entity1636 : study of in vitro @entity134 secretion and immunohistochemical localization of steroidogenic enzymes.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2494 :: ('MESH:D003687', 'Chemical') :: ['DHEA', 'Dehydroepiandrosterone'] @entity699 :: ('MESH:D003480', 'Disease') :: ["Cushing's syndrome"] @entity700 :: ('MESH:C538238', 'Disease') :: ['Adrenal incidentalomas', 'adrenal incidentalomas'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1636 :: ('MESH:D018268', 'Disease') :: ['adrenocortical incidentaloma'] @entity16663 :: ('MESH:D000306', 'Disease') :: ['adrenocortical tumors'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity6192 :: ('1392', 'Gene') :: ['CRH'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity701 :: (MESH:D006854,Chemical) :: ['cortisol']
